Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Stakeholders
2. Research & Forecasting
2.1. Research Methodology
2.1.1. Research Instruments
2.1.1.1. Secondary Instrument
2.1.1.2. Primary Instrument
2.1.2. Research Approaches
2.1.2.1. Bottom-up Approach
2.1.2.2. Top-down Approach
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.1.5. Vendor Inclusion Criteria
2.2. Forecasting Methodology
2.2.1. Methodology for Market Estimation & Forecasting
2.2.2. Significance and Importance of the Market Estimation & Forecasting
3. Executive Summary
4. Premium Insight
4.1. Market Connectivity
4.2. Market Data Feed
4.3. Market Vendor Ranking Analysis
4.4. Market Dynamics
4.4.1. Drivers
4.4.1.1. Growing incidences of cancer
4.4.1.2. Adoption of immunotherapy over other treatment options
4.4.1.3. Development of bioinformatic tools enhancing the drug development process
4.4.1.4. Rise in healthcare expenditure and healthcare insurance
4.4.1.5. Technological advancement and R&D for the treatment of cancer
4.4.2. Restraints
4.4.2.1. High cost associated with the treatment
4.4.3. Opportunities
4.4.3.1. Clinical trials to cure different cancers in immunotherapy
4.4.3.2. Moving toward personalized immunotherapy
4.4.3.3. Combination of modern immunotherapy and traditional medicines increasing survival rate
4.4.4. Challenges
4.4.4.1. Cancer limiting the immune response
4.5. Porter's Five Forces Analysis
4.5.1. Threat of New Entrants
4.5.2. Threat of Substitutes
4.5.3. Bargaining Power of Customers
4.5.4. Bargaining Power of Suppliers
4.5.5. Industry Rivalry
5. Global Cancer Immunotherapy Market, by Function
5.1. Introduction
5.2. Breast Cancer
5.3. Colorectal Cancer
5.4. Head & Neck Cancer
5.5. Lung Cancer
5.6. Melanoma
5.7. Multiple Myeloma
5.8. Prostate Cancer
6. Global Cancer Immunotherapy Market, by Product
6.1. Introduction
6.2. Cell Therapies
6.2.1. Chimeric Antigen Receptor T Cell Therapy
6.2.2. Dendritic Cells
6.3. Checkpoint Inhibitors
6.3.1. Cytotoxic T-Lymphocyte-Associated Protein-4
6.3.2. Programmed Death 1 & Programmed Death Ligand 1
6.4. Immunomodulators
6.4.1. Granulocyte-Macrophage Colony-Stimulating Factor
6.4.2. Interferons
6.4.3. Interleukins
6.4.4. Oncolytic Virus
6.5. Monoclonal Antibodies
6.5.1. Bispecific Monoclonal Antibodies
6.5.2. Conjugated Monoclonal Antibodies
6.5.3. Naked Monoclonal Antibodies
6.6. Vaccines
6.6.1. Prophylactic Vaccines
6.6.2. Therapeutic Vaccines
7. Global Cancer Immunotherapy Market, by End User
7.1. Introduction
7.2. Cancer Research Institutes
7.3. Clinics
7.4. Hospitals
8. Global Cancer Immunotherapy Market, by Geography
8.1. Introduction
8.2. Americas Cancer Immunotherapy Market
8.2.1. Americas Cancer Immunotherapy Market, by Country
8.2.1.1. United States
8.2.1.2. Brazil
8.2.1.3. Canada
8.2.1.4. Mexico
8.2.1.5. Argentina
8.2.2. Americas Cancer Immunotherapy Market, by Function
8.2.3. Americas Cancer Immunotherapy Market, by Product
8.2.4. Americas Cancer Immunotherapy Market, by End User
8.3. Europe, Middle East & Africa Cancer Immunotherapy Market
8.3.1. Europe, Middle East & Africa Cancer Immunotherapy Market, by Country
8.3.1.1. United Kingdom
8.3.1.2. Germany
8.3.1.3. France
8.3.1.4. Saudi Arabia
8.3.1.5. United Arab Emirates
8.3.1.6. Italy
8.3.1.7. Russia
8.3.2. Europe, Middle East & Africa Cancer Immunotherapy Market, by Function
8.3.3. Europe, Middle East & Africa Cancer Immunotherapy Market, by Product
8.3.4. Europe, Middle East & Africa Cancer Immunotherapy Market, by End User
8.4. Asia-Pacific Cancer Immunotherapy Market
8.4.1. Asia-Pacific Cancer Immunotherapy Market, by Country
8.4.1.1. China
8.4.1.2. Japan
8.4.1.3. India
8.4.1.4. Australia
8.4.2. Asia-Pacific Cancer Immunotherapy Market, by Function
8.4.3. Asia-Pacific Cancer Immunotherapy Market, by Product
8.4.4. Asia-Pacific Cancer Immunotherapy Market, by End User
9. 360iResearch Competitive Strategic Window
9.1. Introduction
9.1.1. Leverage Zone
9.1.2. Vantage Zone
9.1.3. Speculative Zone
9.1.4. Bottleneck Zone
10. 360iResearch FPNV Positioning Matrix
10.1. Introduction
10.2. 360iResearch Scores
10.2.1. Forefront
10.2.2. Pathfinders
10.2.3. Niche
10.2.4. Vital
10.3. Business Strategy
10.4. Product Satisfaction
11. Competitive News Feed Analysis
12. Company Usability Profiles
12.1. Amgen Inc.
12.2. Astrazeneca
12.3. Bayer AG
12.4. Bristol-Myers Squibb
12.5. Celgene Corporation
12.6. ELI Lilly and Company
12.7. F. Hoffmann-La Roche Ltd
12.8. GlaxoSmithKline Plc
12.9. Janssen Global Services, LLC
12.10. Merck
12.11. Novartis
12.12. Pfizer
12.13. Seattle Genetics, Inc.
12.14. Spectrum Pharmaceuticals, Inc.
13. Appendix
13.1. Top Reports
13.2. Author Details

LIST OF TABLES (39 TABLES)

TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)
TABLE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET RANKING, BY VENDORS, 2017
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 22. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)
TABLE 23. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)
TABLE 24. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 25. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)
TABLE 26. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)
TABLE 27. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)
TABLE 30. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)
TABLE 31. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2016 - 2024 (USD MILLION)
TABLE 32. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 33. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2016 - 2024 (USD MILLION)
TABLE 34. 360IRESEARCH SCORES FOR FOREFRONT IN CANCER IMMUNOTHERAPY MARKET
TABLE 35. 360IRESEARCH SCORES FOR PATHFINDERS IN CANCER IMMUNOTHERAPY MARKET
TABLE 36. 360IRESEARCH SCORES FOR NICHE IN CANCER IMMUNOTHERAPY MARKET
TABLE 37. 360IRESEARCH SCORES FOR VITAL IN CANCER IMMUNOTHERAPY MARKET
TABLE 38. 360IRESEARCH FPNV POSITIONING MATRIX BUSINESS STRATEGY FOR CANCER IMMUNOTHERAPY MARKET
TABLE 39. 360IRESEARCH FPNV POSITIONING MATRIX PRODUCT SATISFACTION FOR CANCER IMMUNOTHERAPY MARKET

LIST OF FIGURES (35 TABLES)

FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET: YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH METHODOLOGY
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH INSTRUMENTS
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY SECONDARY INSTRUMENT SOURCES
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY POTENTIAL RESPONDENTS
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY BREAKDOWN OF PRIMARY INSTRUMENT
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH APPROACHES
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY DATA TRIANGULATION
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET: KEY RESEARCH ASSUMPTIONS
FIGURE 10. CANCER IMMUNOTHERAPY MARKET: KEY MARKET CONNECTIVITY
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2016 - 2024 (USD MILLION)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2017 VS 2024 (USD MILLION)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD MILLION)
FIGURE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017 VS 2024 (USD MILLION)
FIGURE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GEOGRAPHY, 2017 (USD MILLION)
FIGURE 31. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY FUNCTION, 2024
FIGURE 32. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT, 2024
FIGURE 33. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER, 2024
FIGURE 34. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET, BY GEOGRAPHY, 2024
FIGURE 35. 360IRESEARCH FPNV POSITIONING MATRIX FOR CANCER IMMUNOTHERAPY MARKET